189 related articles for article (PubMed ID: 36971800)
21. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
22. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
[TBL] [Abstract][Full Text] [Related]
23. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
[TBL] [Abstract][Full Text] [Related]
25. Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report.
Hong SH; Kim HD
BMC Ophthalmol; 2024 Apr; 24(1):200. PubMed ID: 38679743
[TBL] [Abstract][Full Text] [Related]
26. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
[TBL] [Abstract][Full Text] [Related]
27. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
Holz FG; Iida T; Maruko I; Sadda SR
Retina; 2022 Sep; 42(9):1629-1637. PubMed ID: 35994582
[TBL] [Abstract][Full Text] [Related]
28. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.
Tanaka K; Koizumi H; Tamashiro T; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Kasai A; Ogasawara M; Shintake H; Sugano Y; Yamamoto A; Kataoka K; Hasegawa T; Izumi T; Kawai M; Maruko R; Sekiryu T; Okada AA; Iida T; Mori R
Jpn J Ophthalmol; 2022 Jul; 66(4):379-385. PubMed ID: 35595951
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of brolucizumab in neovascular age-related macular degeneration: A multicentre retrospective real-world study.
Kim DJ; Kim DG; Kwak HD; Jang JY; Ji YS; Lee SH; Lee EK; Park KH; Kim JH; Lee JS; Song Y; Kim ST; Shin MH; Kim M; Park SJ; Joo K; Sagong M; Lee CS; Woo SJ
Acta Ophthalmol; 2024 May; ():. PubMed ID: 38706195
[TBL] [Abstract][Full Text] [Related]
30. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
32. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
33. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
34. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study.
Alex D; Giridhar A; Gopalakrishnan M; Indurkhya S; Madan S
Indian J Ophthalmol; 2021 Jul; 69(7):1862-1866. PubMed ID: 34146045
[TBL] [Abstract][Full Text] [Related]
35. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
36. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
37. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
[TBL] [Abstract][Full Text] [Related]
38. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
Pokroy R; Mimouni M; Barayev E; Segev F; Geffen N; Nemet AY; Segal O
Retina; 2018 Aug; 38(8):1485-1491. PubMed ID: 28654630
[TBL] [Abstract][Full Text] [Related]
39. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study.
Hirano T; Kumazaki A; Tomihara R; Ito S; Hoshiyama K; Murata T
Sci Rep; 2023 Jul; 13(1):10901. PubMed ID: 37407660
[TBL] [Abstract][Full Text] [Related]
40. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
